Commercial Strategy and Execution for Life Sciences
From Science to Patients
Decode is a global life science advisory firm. Since 2012 we have helped biotech, biopharma and medtech companies bring needed therapies to market and build corporate value
Who we work with
Services
Depth in every commercial function
One partner across the commercial organization, from a first launch to an established portfolio. Every program is sized to the asset, the stage and the company
Sized to every stage
Commercial input belongs alongside drug development, not exclusively during Phase 3. We time each workstream to the business decisions that shape an asset’s value, from indication selection and trial design to formulation, dosing and label.
Unmet need and competitive landscape
Opportunity valuation
Commercial input on trial design
Draft label and trade name
L-12 execution critical path
Launch readiness dashboard
Lifecycle and LOE planning
Partnerships and global expansion
Enterprise transformation
From R&D organization to commercial-stage company, with commercial strategy integrated into every corporate function.
Capital strategy and IR
GTN and government reporting
Recruiting, staffing, training
PR and internal communications
Data infrastructure and BI
Serialization integration
Medical messaging and positioning
Publications and congresses
Compliance build and SOPs
Vendor contracts, data privacy
CMO and 3PL management
Forecast and safety stock
Alliance management
Global expansion
Commercial input on trial design
Label optimization
Approach
An extension of your team
We advise boards and leadership teams, build the commercial strategy and execute it, staffing critical roles until your organization is in place. Engage us for one capability or all three.
Insights-Based Advisory
Evidence from customers, markets and competitors, translated into clear commercial decisions. AI-enabled research synthesis compresses weeks of work into days.
Strategy Development
A disease-appropriate commercial strategy, right-sized to the company, with a critical path built back from launch.
Full-Time & Fractional Operational Excellence
Senior operators who execute the plan, in full-time or fractional roles, until your team is built.
Experience
Deep experience acrosss therapeutic areas and modalities
Specialists in first launches, with equal depth in established brands, relaunches and lifecycle programs, at large pharma and emerging biotech.
Disease Areas
Launch, lifecycle and clinical-stage programs, by indication.
Modalities
Commercial models shaped by the science, from high-COGS cell and gene therapies to small molecules and devices.
Team
Senior leadership for every engagement
Carolina Petrini
Managing Partner, Chief Commercial Officer (full & fractional)
– Carolina is a commercial executive and board member with 26 years across biopharma, biotech and medtech. She has led commercial strategy, four specialty launches, each meeting or exceeding its launch KPIs, and contributed to more than 37 launch, relaunch and readiness programs, including BioPharma Dive’s Drug Launch of the Year.
– Her work starts long before launch: indication selection and sequencing, target product profiles, pricing corridors and payer-validated forecasts used directly in Board and investment decisions. She designs and builds commercial organizations from a blank page, go-to-market strategy, and has held P&L responsibility of $80M to $150M.
– Carolina has worked as a full-time, fractional and interim CCO in emerging biotech and inside large, matrixed organizations, alongside headquarters in Europe, Asia and Latin America.
Board and investor work
– Carolina is a commercial executive and board member with 26 years across biopharma, biotech and medtech. She has led commercial strategy, four specialty launches, each meeting or exceeding its launch KPIs, and contributed to more than 37 launch, relaunch and readiness programs, including BioPharma Dive’s Drug Launch of the Year.
– Her work starts long before launch: indication selection and sequencing, target product profiles, pricing corridors and payer-validated forecasts used directly in Board and investment decisions. She designs and builds commercial organizations from a blank page, go-to-market strategy, and has held P&L responsibility of $80M to $150M.
– Carolina has worked as a full-time, fractional and interim CCO in emerging biotech and inside large, matrixed organizations, alongside headquarters in Europe, Asia and Latin America.
Expertise curated for each engagement
Former commercial leaders from large pharma and emerging biotech, with deep disease area expertise. We assemble the experts each asset, stage and company requires.